Pneumonitis from immune checkpoint inhibitors and COVID-19: Current concern in cancer treatment

Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora

Research output: Contribution to journalReview articlepeer-review


Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.

Original languageEnglish
Article numbere000952
JournalJournal for ImmunoTherapy of Cancer
Issue number2
Publication statusPublished - Jul 21 2020


  • CTLA-4 Antigen
  • cytokines
  • immunotherapy
  • melanoma
  • programmed cell death 1 receptor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Pneumonitis from immune checkpoint inhibitors and COVID-19: Current concern in cancer treatment'. Together they form a unique fingerprint.

Cite this